
Loading, please wait...

Loading, please wait...

Clinicians often hesitate to recommend aggressive surgery for elderly patients based on chronological age. However, a recent landmark study suggests that glottic cancer mortality TOLMS outcomes do not depend on how old a patient is at diagnosis. These findings emphasize that surgeons should prioritize tumor biology and surgical margins over a simple birth date.
The retrospective analysis followed 676 patients with pT1-3 laryngeal squamous cell carcinoma who underwent primary transoral laser microsurgery (TOLMS). Researchers used advanced competing-risk models to distinguish between cancer deaths and mortality from other causes. While overall survival decreased per decade, the risk of dying specifically from cancer did not show a meaningful statistical increase. Specifically, the pT category and margin status were the dominant predictors of disease-specific mortality.
Consequently, elderly patients with favorable tumor characteristics often achieve excellent results comparable to younger cohorts. Additionally, non-cancer causes like cardiovascular disease accounted for most deaths in older patients. This study clarifies that apparent age-related differences in survival largely reflect competing mortality rather than cancer progression.
In the Indian context, where tobacco-related glottic cancers are prevalent, these results provide a strong rationale for maintaining curative intent in the elderly. Therefore, functional status and disease stage should guide the decision to perform TOLMS rather than an arbitrary age cutoff. Moreover, ensuring clear surgical margins remains the most critical factor for long-term success. Surgeons should offer TOLMS to any patient who is medically fit for anesthesia, regardless of chronological age.
Age itself does not compromise laryngeal preservation. Instead, the tumor's extent and the surgeon's ability to achieve negative margins determine the oncological outcome.
The pT category and positive surgical margins were the dominant predictors of death from disease, whereas chronological age was not a significant factor in competing-risk analysis.
Disclaimer: This content is for informational and educational purposes only. It is not intended as medical advice or a substitute for professional clinical judgment. Refer to the latest local and national guidelines for clinical practice.
References
Chu F et al. Age Does Not Influence Cancer Mortality After Transoral Laser Microsurgery for Glottic Cancer: A Competing-Risks Analysis of 676 Patients. Head Neck. 2026 May 18. doi: 10.1002/hed.70321. PMID: 42151741.
Pradhan SA. Treatment Decision in the Management of Laryngeal Cancer: An Indian Perspective. AIJOC. 2024.

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


Analysis of 676 patients shows that chronological age does not predict cancer-specific mortality after TOLMS for glottic cancer; tumor stage and margins mat...
5 months ago

Novel diimide and hydrazone scaffolds, particularly compound #C4, synergistically reactivate latent HIV-1 when combined with JQ1 or PKC activators. Demonstrating donor-matched proviral transcription ex vivo and non-canonical signaling, these findings advance shock and kill strategies toward reservoir eradication.
Today

A comparative cohort study evaluates vNOTES vs TLH hysterectomy for benign conditions, demonstrating shorter operative duration, faster return to daily activities, and equivalent female sexual function scores without increased dyspareunia.
Today

Review how tailored exercise programs benefit frail older patients with heart failure. Explore pathophysiological mechanisms, individualized training prescriptions, and strategies to overcome adherence barriers in clinical practice.
Yesterday

This comparative study evaluates posterior labral tears with and without glenohumeral instability, highlighting distinct demographic patterns, MRI underestimation in stable shoulders, and successful arthroscopic repair outcomes.
Yesterday

A clinical study demonstrates that early intervention with tocilizumab, either as monotherapy or bridged with corticosteroids, achieves significant proptosis reduction and resolves active inflammation in treatment-naive thyroid eye disease.
Today